OrbiMed Raises $1.86B for Healthcare Royalty & Credit Fund V
Gunderson Dettmer represented OrbiMed, a leading global healthcare investment firm, in the formation of its $1.86 billion OrbiMed Royalty and Credit Opportunities Fund V.
Fund V will seek to provide tailored investment solutions to growth-oriented healthcare companies, with a focus on non-dilutive credit and royalty-based financing. OrbiMed expects to partner with healthcare companies across many sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
Investors in this new fund include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
In the announcement of the fund formation, OrbiMed Managing Partner Carter Neild said, “Over 90% of Fund V's committed capital is from existing, long-standing firm relationships. We are grateful for this support, and will endeavor to deliver exceptional results to our partners.”
The Gunderson deal team was led by Tyler Kirtley and Malcolm Nicholls and included Joe Chase-Fielding, Sarah Anischik, Luke Charette, Bria Guitano and Gabrielle Paradis.
Companies
OrbiMed